. home.aspx



MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG

February 15, 2021 / Shivaji Dound

MindMed, a leading psychedelic medicine biotech company announced another partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties.

As a component of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have just been combined by MindShift Compounds AG and related patent applications were documented by MindMed. MindMed plans to begin first-in-human Phase 1 clinical trials as ahead of schedule as Q1 2022 through its existing clinical preliminary stage for psychedelic and empathogenic compounds in Switzerland.

The partnership on these initial targets will expand MindMed's current, grounded clinical pipeline with extra reinforcement and expansion compounds with comparative and possibly improved restorative properties. The connected combination intellectual property and drug technology will be possessed through and through by MindMed, and MindShift Compounds AG will give all intellectual property identified with the new psychedelic compounds only to MindMed.

This partnership adds to MindMed's existing IP portfolio development endeavors in progress in collaboration with the University Hospital Basel's Liechti Lab for exemplary psychedelic compounds including LSD, MDMA, Psilocybin, MDMA-LSD combinations, personalized dosing technologies and a LSD Neutralizer technology, which depend on multiple clinical trials and long stretches of exploration led by the Liechti Lab.

MindMed plans to work with the accomplished drug discovery group at MindShift Compounds AG to encourage extensively cover preclinical psychedelics investigation into novel compounds and hopes to continue to record a substantial number of licenses on countless novel substance matters, production innovations, and later clinical applications, allowing MindMed to additionally unite its leading situation in the in general psychedelic-medicine market as it moves these next-gen compounds into the clinic through advanced patient clinical trials.

MindShift CEO, Dr. Felix Lustenberger, said "Our innovative psychedelic drug-discovery platform based in Switzerland is pioneering next-gen psychedelic compounds that complement in a synergistic pipeline approach the later-stage development work underway at MindMed. The compounds we are working on are typically derivatives or analogues of known substances with psychedelic properties, such as phenethylamines, tryptamines, and ergolines, and are therefore enhanced versions of both the established and classic psychedelic compounds such as mescaline, psilocybin, DMT, and LSD, as well as compounds with expected combined psychedelic-empathogenic effect profiles. These novel chemical structures, for example MDMA and LSD-like compounds, are designed and synthesized with expected ameliorated psychoactive properties and duration-of-effect profiles with potential added therapeutic benefits."

About MindMed
MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic-inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the company's groundbreaking approach to developing the next generation of psychedelic-inspired medicines and therapies.